Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

Vold Vision

Neither a doctor nor a teaching hospital

Research payments

$643,327

80 payments

Through program year 2024, Vold Vision is reported as receiving $643,327 in research payments, across 80 payments.

By program year

5 rows
Year Kind Amount Payments
2024 Research $5,405 3
2022 Research $34,028 3
2021 Research $314,987 25
2020 Research $155,911 18
2019 Research $132,997 31

Breakdown

Who paid Research payments · program years 2019–2024
  1. Sight Sciences, Inc. $261,695 27 payments
  2. Glaukos Corporation $217,566 38 payments
  3. Carl Zeiss Meditec, Inc. $137,016 6 payments
  4. Bausch & Lomb Americas Inc. $20,028 2 payments
  5. RxSight Inc $5,405 3 payments
  6. Allergan Inc. $1,617 4 payments
Studies the money was for Research payments · program years 2019–2024
  1. Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5 $90,077 14 payments
  2. A Prospective Multicenter Study of the OMNI Surgical System in Pseudophakic Eyes with Open Angle Glaucoma (ORION) $80,200 2 payments
  3. Prospective Multicenter Post Market Study of Use of the OMNI Surgical System in Combination with Cataract Extraction in Open Angle Glaucoma $74,676 3 payments
  4. Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5% $70,724 12 payments
  5. Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5 $56,765 12 payments
  6. A Prospective Multicenter Clinical Study To Evaluate The Safety And Effectiveness of the MEL 90 Excimer Laser Using LASIK (Laser in Situ Keratomileusis) for the Correction of Myopia, Hyperopia, Astigmatism and Mixed Astigmatism. $36,206 1 payment
  7. Prospective Multicenter Post Market Study of Use of the OMNI Surgical System in Combination with Cataract Extraction in Open Angle Glaucoma (GEMINI) $33,506 2 payments
  8. A Prospective Multicenter Clinical Study To Evaluate The Safety And Effectiveness of the MEL 90 Excimer Laser Using LASIK (Laser in Situ Keratomileusis) for the Correction of Myopia, Hyperopia, Astigmatism and Mixed Astigmatism. $25,828 1 payment
  9. A Prospective Multicenter Clinical Study To Evaluate The Safety And Effectiveness of the MEL 90 Excimer Laser Using LASIK (Laser in Situ Keratomileusis) for the Correction of Myopia, Hyperopia, Astigmatism and Mixed Astigmatism. $24,528 1 payment
  10. A Prospective Multicenter Clinical Study To Evaluate The Safety And Effectiveness of the MEL 90 Excimer Laser Using LASIK (Laser in Situ Keratomileusis) for the Correction of Myopia, Hyperopia, Astigmatism and Mixed Astigmatism. $24,246 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record